Annovis Bio, Inc. (ANVS): auditor change — Annovis Bio dismisses auditor Withum, appoints EY; material weakness triggered restatement

Annovis Bio, Inc.

Withum dismissed as auditor effective May 25, 2023; EY appointed for fiscal 2023.
Withum's 2022 audit report included a going-concern explanatory paragraph.
Material weakness in internal controls over R&D expense classification led to restatement of 2022 quarterly financials.
No disagreements with Withum on accounting principles or practices.
Restatement affected three months ended March 31, 2022, and subsequent quarters through September 2022.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Annovis Bio, Inc. dismissed WithumSmith+Brown PC as its auditor.

Action: dismissal
Auditor: WithumSmith+Brown PC
Successor: Ernst & Young LLP

Exact text from the filing

Dismissal of Independent Registered Public Accounting Firm On May 25, 2023, the Audit Committee (the “Audit Committee”) of the Board of Directors of Annovis Bio, Inc. (the “Company”) dismissed WithumSmith+Brown PC (“Withum”) as the Company’s independent registered public accounting firm.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Annovis Bio, Inc. engaged Ernst & Young LLP as its auditor.

Action: engagement
Auditor: Ernst & Young LLP

Exact text from the filing

Engagement of New Independent Registered Public Accounting Firm Effective May 25, 2023, the Audit Committee approved the appointment of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

Browse all auditor changes →

Annovis Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-066171

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.